$ARQT
Arcutis Biotherapeutics Inc Stock $arqt

$arqt Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000178730623000044 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$5.190M	$2.781M	$0.00
YoY Change
Cost Of Revenue	$776.0K	$783.0K
YoY Change
Gross Profit	$4.414M	$1.998M
YoY Change
Gross Profit Margin	85.05%	71.84%
Selling, General & Admin	$45.96M	$42.92M	$22.01M
YoY Change	66.38%	95.03%	52.29%
% of Gross Profit	1041.19%	2148.05%
Research & Development	$25.22M	$35.35M	$40.62M
YoY Change	-33.99%	-12.99%	87.8%
% of Gross Profit	571.34%	1769.02%
Depreciation & Amortization	$198.0K	$175.0K	$150.0K
YoY Change	27.74%	16.67%	53.06%
% of Gross Profit	4.49%	8.76%
Operating Expenses	$71.95M	$79.05M	$62.63M
YoY Change	9.31%	26.22%	73.56%
Operating Profit	-$66.76M	-$76.27M	-$62.63M
YoY Change	1.42%	21.77%	73.56%
Interest Expense	$7.349M	$7.042M	$1.838M
YoY Change	267.45%	283.13%
% of Operating Profit
Other Income/Expense, Net	-$4.228M	-$3.835M	-$1.696M
YoY Change	167.76%	126.12%	-4044.19%
Pretax Income	-$70.99M	-$80.10M	-$64.32M
YoY Change	5.32%	24.53%	78.48%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$70.99M	-$80.10M	-$64.32M
YoY Change	5.32%	24.53%	78.47%
Net Earnings / Revenue	-1367.84%	-2880.26%
Basic Earnings Per Share	-$1.16	-$1.31	-$1.27
Diluted Earnings Per Share	-$1.16	-$1.31	-$1.27
COMMON SHARES
Basic Shares Outstanding	61.42M shares	61.08M shares	50.51M shares
Diluted Shares Outstanding	61.43M shares	61.17M shares	50.51M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$268.7M	$332.4M	$343.6M
YoY Change	-4.78%	-3.26%	-22.77%
Cash & Equivalents	$105.1M	$81.41M	$69.80M
Short-Term Investments	$163.6M	$251.0M	$273.8M
Other Short-Term Assets	$12.52M	$13.95M	$14.96M
YoY Change	-5.59%	-6.71%	-26.69%
Inventory	$10.47M	$8.551M
Prepaid Expenses
Receivables	$17.21M	$12.77M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$308.9M	$367.7M	$358.9M
YoY Change	4.55%	2.44%	-22.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.867M	$2.070M	$2.152M
YoY Change	-10.15%	-3.81%	2.77%
Goodwill
YoY Change
Intangibles	$6.812M	$7.000M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$596.0K	$78.00K	$78.00K
YoY Change	664.1%	0.0%	0.0%
Total Long-Term Assets	$11.82M	$11.78M	$5.191M
YoY Change	134.64%	126.97%	-4.59%
TOTAL ASSETS
Total Short-Term Assets	$308.9M	$367.7M	$358.9M
Total Long-Term Assets	$11.82M	$11.78M	$5.191M
Total Assets	$320.7M	$379.5M	$364.1M
YoY Change	6.73%	4.22%	-22.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.16M	$12.49M	$12.47M
YoY Change	103.34%	0.15%	296.25%
Accrued Expenses	$18.81M	$23.86M	$19.99M
YoY Change	1.87%	19.38%	64.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$36.66M	$37.03M	$32.96M
YoY Change	33.39%	12.32%	115.25%
LONG-TERM LIABILITIES
Long-Term Debt	$199.8M	$198.8M	$72.74M
YoY Change	173.14%	173.24%
Other Long-Term Liabilities	$3.755M	$3.938M	$19.00K
YoY Change	31191.67%	20626.32%	-67.24%
Total Long-Term Liabilities	$199.8M	$198.8M	$72.76M
YoY Change	173.09%	173.17%	125350.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.66M	$37.03M	$32.96M
Total Long-Term Liabilities	$199.8M	$198.8M	$72.76M
Total Liabilities	$240.2M	$239.7M	$110.3M
YoY Change	128.57%	117.27%	440.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$870.9M	-$799.9M	-$472.6M
YoY Change	61.28%	69.26%	98.57%
Common Stock	$6.000K	$6.000K	$5.000K
YoY Change	20.0%	20.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$80.51M	$139.7M	$253.8M
YoY Change
Total Liabilities & Shareholders Equity	$320.7M	$379.5M	$364.1M
YoY Change	6.73%	4.22%	-22.76%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$70.99M	-$80.10M	-$64.32M
YoY Change	5.32%	24.53%	78.47%
Depreciation, Depletion And Amortization	$198.0K	$175.0K	$150.0K
YoY Change	27.74%	16.67%	53.06%
Cash From Operating Activities	-$66.49M	-$80.34M	-$56.98M
YoY Change	7.27%	41.02%	23.31%
INVESTING ACTIVITIES
Capital Expenditures	$276.0K	$82.00K	$124.0K
YoY Change	-445.0%	-33.87%	-77.62%
Acquisitions
YoY Change
Other Investing Activities	$89.39M	$107.8M	$15.42M
YoY Change	69.81%	599.26%	-75.35%
Cash From Investing Activities	$89.12M	$107.8M	$15.30M
YoY Change	69.54%	604.39%	-75.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.067M	$100.0K	$14.72M
YoY Change	-5.66%	-99.32%	-92.92%
NET CHANGE
Cash From Operating Activities	-66.49M	-$80.34M	-$56.98M
Cash From Investing Activities	89.12M	$107.8M	$15.30M
Cash From Financing Activities	1.067M	$100.0K	$14.72M
Net Change In Cash	23.70M	$27.46M	-$26.96M
YoY Change	-386.09%	-201.83%	-112.06%
FREE CASH FLOW
Cash From Operating Activities	-$66.49M	-$80.34M	-$56.98M
Capital Expenditures	$276.0K	$82.00K	$124.0K
Free Cash Flow	-$66.76M	-$80.43M	-$57.10M
YoY Change	7.85%	40.85%	22.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001787306
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39186
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ARCUTIS BIOTHERAPEUTICS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-2974255
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3027 Townsgate Road
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Westlake Village
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91361
CY2023Q1	dei	City Area Code CityAreaCode	805
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	418-5006
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
CY2023Q1	dei	Trading Symbol TradingSymbol	ARQT
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61422282	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81405000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53641000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	925000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1234000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12769000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8458000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	251000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	355948000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	8551000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	7514000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13026000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10611000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	367676000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	437406000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2070000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1881000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7188000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2634000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2721000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	78000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	78000	usd
CY2023Q1	us-gaap	Assets Assets	379458000	usd
CY2022Q4	us-gaap	Assets Assets	449274000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12485000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8827000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23864000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28323000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	676000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	657000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	37025000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37807000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3938000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4117000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	198763000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	197769000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	239726000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	239693000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61369061	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61052250	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61357932	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61037403	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	940004000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	930425000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-414000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1086000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-799864000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-719764000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	139732000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	209581000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	379458000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	449274000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2781000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2781000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
CY2023Q1	arqt	Cost Of Sales CostOfSales	783000	usd
CY2022Q1	arqt	Cost Of Sales CostOfSales	0	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35345000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40622000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42918000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22006000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	79046000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	62628000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-76265000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-62628000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3207000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	142000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	7042000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	1838000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3835000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1696000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-80100000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-64324000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	724000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-765000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-52000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	672000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-765000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-79428000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-65089000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.27
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.27
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61169089	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61169089	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50513524	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50513524	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	297677000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	260000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2022Q1	arqt	Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises	25000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6533000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-765000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-64324000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	253772000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	209581000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	63000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q1	arqt	Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises	37000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9479000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	724000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-52000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-80100000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	139732000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-80100000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-64324000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	175000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	150000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	87000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	79000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	188000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2161000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-618000	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	994000	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	392000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9479000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6533000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4311000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1037000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2415000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3376000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5196000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4459000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5532000	usd
CY2023Q1	arqt	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-160000	usd
CY2022Q1	arqt	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-87000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-80344000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-56975000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	39667000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	55504000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	147500000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	70925000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	124000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	107751000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15297000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	261000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14455000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14716000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-52000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27455000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26962000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54875000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97991000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82330000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71029000	usd
CY2023Q1	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	5999000	usd
CY2022Q1	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	1425000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-799900000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-719800000	usd
CY2023Q1	arqt	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	333300000	usd
CY2022Q4	arqt	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	410800000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to revenue recognition, accruals for research and development activities, stock-based compensation expense, and income taxes. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates.</span></div>
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	900000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	usd
CY2022Q3	arqt	Intangible Assets Milestone Payment IntangibleAssetsMilestonePayment	7500000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53641000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q1	arqt	Pre Commercial Inventory PreCommercialInventory	12700000	usd
CY2022Q4	arqt	Pre Commercial Inventory PreCommercialInventory	14100000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	562000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	750000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	750000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	750000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	750000	usd
CY2023Q1	arqt	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	3438000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7000000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit Risk and Other Risks and Uncertainties<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by either the financial institutions holding its cash or by its customers owing trade receivables to the extent recorded on the condensed consolidated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>balance sheets. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses.
CY2023Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2022Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	81405000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	251362000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	58000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	420000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	251000000	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	332405000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	409589000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81405000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	53641000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	357034000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1093000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	355948000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6461000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5659000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	183000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	395000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1907000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1460000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	8551000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	7514000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	2199000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	956000	usd
CY2023Q1	arqt	Prepaid Copay Assistance Program PrepaidCopayAssistanceProgram	1876000	usd
CY2022Q4	arqt	Prepaid Copay Assistance Program PrepaidCopayAssistanceProgram	3226000	usd
CY2023Q1	arqt	Prepaid Clinical Trial Test Costs Current PrepaidClinicalTrialTestCostsCurrent	1135000	usd
CY2022Q4	arqt	Prepaid Clinical Trial Test Costs Current PrepaidClinicalTrialTestCostsCurrent	172000	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	7816000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	6257000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13026000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10611000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	995000	usd
CY2023Q1	arqt	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	8196000	usd
CY2022Q4	arqt	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	7896000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5990000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14000000	usd
CY2023Q1	arqt	Accrued Sales Deductions Current AccruedSalesDeductionsCurrent	3125000	usd
CY2022Q4	arqt	Accrued Sales Deductions Current AccruedSalesDeductionsCurrent	1567000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6553000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4860000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23864000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28323000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1024000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1054000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3399000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3034000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1329000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1153000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2070000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1881000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	175000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	150000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	724000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1087000	usd
CY2023Q1	arqt	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	653000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5537000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	923000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4614000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	676000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3938000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4614000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	189000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	171000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	241000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	176000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2023Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	5100000	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	800000	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	800000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	200000000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	200000000	usd
CY2023Q1	arqt	Debt Instrument Accrued Final Fee DebtInstrumentAccruedFinalFee	2611000	usd
CY2022Q4	arqt	Debt Instrument Accrued Final Fee DebtInstrumentAccruedFinalFee	1871000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3848000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	4102000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	198763000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	197769000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	213900000	usd
CY2023Q1	arqt	Common Stock Voting Rights Number Of Votes Per Share CommonStockVotingRightsNumberOfVotesPerShare	1	vote
CY2023Q1	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	usd
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15572939	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12837138	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7476223	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.93
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M23D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	18667000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1022350	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.76
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	31497	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.22
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	108008	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	22.15
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	15308	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	26.22
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8343760	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.44
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M15D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11983000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3805706	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	17.43
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y11M12D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11132000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6200000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.93
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9479000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6533000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11260780	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8274334	shares

Files In Submission

Name	View Source	Status
arqt-20230331_cal.xml	Edgar Link	unprocessable
arqt-20230331_pre.xml	Edgar Link	unprocessable
0001787306-23-000044-index-headers.html	Edgar Link	pending
0001787306-23-000044-index.html	Edgar Link	pending
0001787306-23-000044.txt	Edgar Link	pending
0001787306-23-000044-xbrl.zip	Edgar Link	pending
arqt-20230331.htm	Edgar Link	pending
arqt-20230331.xsd	Edgar Link	pending
exhibit311ceoq12023.htm	Edgar Link	pending
exhibit312cfoq12023.htm	Edgar Link	pending
exhibit321ceocfoq12023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
arqt-20230331_def.xml	Edgar Link	unprocessable
arqt-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
arqt-20230331_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARQT
Arcutis Biotherapeutics Inc Stock $arqt

2023 Q2 Form 10-Q Financial Statement

#000178730623000044 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARQT Arcutis Biotherapeutics Inc Stock $arqt

2023 Q2 Form 10-Q Financial Statement

#000178730623000044 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARQT
Arcutis Biotherapeutics Inc Stock $arqt